Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Fineline Cube Apr 30, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Drug

CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction

Fineline Cube May 12, 2025

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG

Fineline Cube May 12, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...

Company Deals Drug

Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development

Fineline Cube May 12, 2025

China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...

Company Drug

InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL

Fineline Cube May 12, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...

Company

AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi

Fineline Cube May 12, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small...

Company Drug

IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma

Fineline Cube May 12, 2025

China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...

Company Drug

Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity

Fineline Cube May 12, 2025

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...

Company Drug

RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis

Fineline Cube May 12, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...

Company Drug

NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million

Fineline Cube May 12, 2025

Shenzhen-based XtalPi Holdings Limited (HKG: 2228) announced plans to acquire a 90% stake in Re...

Company Medical Device

Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters

Fineline Cube May 12, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Drug

Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval

Fineline Cube May 9, 2025

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...

Company Drug

J&J’s Tremfya Approved for Ulcerative Colitis in China

Fineline Cube May 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...

Policy / Regulatory

China’s CDE Reveals 93rd Batch of Reference Preparations for GQCE

Fineline Cube May 9, 2025

China’s Center for Drug Evaluation (CDE) has released the 93rd batch of reference preparations for...

Policy / Regulatory

NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management

Fineline Cube May 9, 2025

The National Health Commission (NHC) this week released the “Guidelines for the Construction and Management...

Company

Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales

Fineline Cube May 9, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April...

Company

Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress

Fineline Cube May 9, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report...

Company Drug

Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials

Fineline Cube May 9, 2025

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...

Company Deals Hospital

Prudential Hong Kong Collaborates with Foshan Fosun Chancheng Hospital for Direct Payment Services

Fineline Cube May 9, 2025

Prudential Hong Kong Limited, a subsidiary of UK-based Prudential plc, has entered into a strategic...

Company Deals

Sanyou Medical Partners with CGBio to Launch Regenerative Medicine Joint Venture

Fineline Cube May 9, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture...

Posts pagination

1 … 158 159 160 … 659

Recent updates

  • Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate
  • Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Company

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.